Prestige Consumer Healthcare Inc., along with its various divisions, is involved in the creation, production, promotion, and distribution of non-prescription health and personal care items across both domestic (U.S.) and global markets. The company's business activities are structured into two principal areas: North American Over-the-Counter Healthcare and International Over-the-Counter Healthcare. Their extensive brand catalog features a diverse array of consumer health solutions, including popular choices for pain relief (such as BC/Goody's), infant care (Boudreaux's Butt Paste), sore throat remedies (Chloraseptic), vision care (Clear Eyes, TheraTears), wart treatment (Compound W), dental hygiene (DenTek), earwax removal (Debrox), and motion sickness prevention (Dramamine). The product line further extends to include digestive aids (Fleet, Gaviscon), cough suppressants (Luden's), feminine hygiene items (Monistat, Summer's Eve), treatments for lice and parasites (Nix), nasal washes (Fess), and rehydration therapies (Hydralyte). These offerings reach consumers through a wide range of retail channels, such as large discount retailers, pharmacies, supermarkets, dollar stores, convenience outlets, membership-based clubs, and digital commerce platforms. Founded in 1996 and based in Tarrytown, New York, the organization operated under the name Prestige Brands Holdings, Inc. until its rebranding to Prestige Consumer Healthcare Inc. in August 2018.

Zerillo Jeffrey

BYOM JOHN E

Recent economic data shows PCE inflation came in softer than expected while Q2 GDP exceeded expectations. The market is now focused on the upcoming Friday employment report. Two stocks highlighted as strong buys are BP, an integrated energy company with a Zacks Rank #1 and improving earnings estimates, and Prestige Consumer Healthcare, also with a Zacks Rank #1 rating.

Best Value Stocks to Buy for October 1st

A comparison of two Medical-Products stocks reveals that Prestige Consumer Healthcare (PBH) offers superior value compared to Neogen (NEOG). While both companies share a Zacks Rank #2 (Buy) rating with improving earnings outlooks, PBH demonstrates significantly better valuation metrics with a forward P/E of 10.26 versus NEOG's 41.51, a PEG ratio of 1.47 versus 4.15, and a Value grade of A versus D.

Prestige Brand Holdings Inc (PBH) Stock Price, Analysis & Trade Signals